Yvette Tomacruz
Internal Medicine · Lubbock, TXNPI 1700018991
Payments from drug & device makers
Across 289 payments — averaging $20.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Otsuka America Pharmaceutical, Inc.$896
- Vifor Pharma, Inc.$676
- OPKO Pharmaceuticals, LLC$648
- Amgen$628
- Bayer$310
- plus $2K from 20 others
What the payments were for
- Speaking & faculty fees$2003%
- Food & beverage$5,57094%
- Education$1673%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 47 | $1,036 |
| Otsuka America Pharmaceutical, Inc. | 48 | $896 |
| Vifor Pharma, Inc. | 29 | $676 |
| OPKO Pharmaceuticals, LLC | 37 | $648 |
| Amgen(2 entities) | 20 | $628 |
| Bayer | 19 | $310 |
| ANI Pharmaceuticals, Inc. | 9 | $288 |
| Daiichi Sankyo Inc. | 14 | $279 |
| GSK | 21 | $278 |
| Fresenius USA Marketing, Inc. | 9 | $187 |
| Mallinckrodt Hospital Products Inc. | 8 | $162 |
| Calliditas Therapeutics US Inc. | 4 | $142 |
| Novartis | 4 | $77 |
| Travere Therapeutics, Inc. | 5 | $69 |
| Ultragenyx Pharmaceutical Inc. | 3 | $53 |
| Akebia Therapeutics Inc | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Boehringer Ingelheim | 1 | $23 |
| Mallinckrodt Enterprises LLC | 1 | $22 |
| Amicus Therapeutics, Inc. | 1 | $19 |
| Genentech USA, Inc. | 1 | $16 |
| Medtronic | 1 | $16 |
| W. L. Gore & Associates, Inc. | 1 | $16 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $15 |
| Boston Scientific | 1 | $14 |
| Baxter Healthcare | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veltassa$200
- Tavneos$124
- PURIFIED CORTROPHIN GEL$123
- JYNARQUE$121
How this compares
$5,937 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RayaldeeCalcifediol | 14 | $16,792 |
| VeltassaPatiromer Calcium Sorbitex | 11 | $13,088 |
| FarxigaDapagliflozin Propanediol | 11 | $7,256 |
| Sevelamer Carbonate | 17 | $2,634 |
| ProsolParenteral Amino Acid 20% No.1 | 11 | $2,008 |
| Allopurinol | 66 | $618 |
| Tamsulosin Hcl | 25 | $368 |
| Furosemide | 46 | $286 |
| Raloxifene Hcl | 13 | $216 |
| Pantoprazole Sodium | 17 | $212 |
| Losartan Potassium | 30 | $201 |
| Lisinopril | 26 | $176 |
| Clonidine Hcl | 17 | $158 |
| Nifedipine ErNifedipine | 13 | $127 |
| Irbesartan | 11 | $104 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| OPKO Pharmaceuticals, LLCRayaldee | $648 | $16,79214 claims |
| AstraZenecaFarxiga | $1,036 | $7,25611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Lubbock
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
- Salma SaigerMesquite$16.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.